secwatch.observer — SEC 8-K summary
======================================

Issuer:     BioAtla, Inc. (BCAB)
CIK:        0001826892
Form:       8-K
Filed at:   2025-05-06T23:59:59+00:00
Accession:  0000950170-25-064415
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

BioAtla Q1 net loss $15.3M; cash $32.4M; Mec-V shows 59% 2-year OS in mKRAS NSCLC
--------------------------------------------------------------------------------

- Net loss $15.3M vs $23.2M YoY; R&D expenses down to $12.4M from $18.9M.
- Cash $32.4M at March 31, 2025; expects runway beyond key readouts in 1H 2026.
- BA3182 Phase 1 dose-escalation ongoing; data readout mid-2025; three patients dosed at 300 µg.
- Mec-V in mKRAS NSCLC shows 67% 1-year and 59% 2-year landmark OS (SOC <20%).
- Oz-V in HPV+ SCCHN: 45% ORR (5/11), 100% disease control; Fast Track discussions with FDA.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1826892/000095017025064415/0000950170-25-064415-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1826892/000095017025064415/bcab-20250506.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-064415

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer